Levetiracetam

  • P. N. Patsalos
Chapter

Abstract

Levetiracetam (Fig. 1) corresponds chemically to (S)-alpha-ethyl-2 oxo-1-pyrrolidine acetamide with an empirical formula of C8H14N2O2 and a molecular weight of 170.21.

References

  1. 1.
    Freitas-Lima P, Alexandre V, Pereira LRL, Feletti F, Perucca E, Sakamoto AC. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Res. 2011;94:117–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationships of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis. CNS Drugs. 2012;26:79–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CB, Shields WD. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–53.PubMedCrossRefGoogle Scholar
  7. 7.
    May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25:690–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother. 2004;13:1–168.Google Scholar
  10. 10.
    Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44:171–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations